These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 37515588

  • 21. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A, Ashida K, Watanabe M, Moritaka K, Sonezaki A, Kitajima Y, Takahashi H, Yoshinobu S, Iwata S, Yasuda J, Hasuzawa N, Ozono S, Motomura S, Nomura M.
    Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866
    [Abstract] [Full Text] [Related]

  • 22. The relationship between gluconeogenic substrate supply and glucose production in humans.
    Jahoor F, Peters EJ, Wolfe RR.
    Am J Physiol; 1990 Feb; 258(2 Pt 1):E288-96. PubMed ID: 2407133
    [Abstract] [Full Text] [Related]

  • 23. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
    Meral R, Malandrino N, Walter M, Neidert AH, Muniyappa R, Oral EA, Brown RJ.
    J Clin Endocrinol Metab; 2022 Mar 24; 107(4):e1739-e1751. PubMed ID: 34677608
    [Abstract] [Full Text] [Related]

  • 24. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G, Akinci B.
    Recent Pat Endocr Metab Immune Drug Discov; 2015 Mar 24; 9(2):74-8. PubMed ID: 26556498
    [Abstract] [Full Text] [Related]

  • 25. Glucagon changes substrate preference in gluconeogenesis.
    Xu H, Wang Y, Kwon H, Shah A, Kalemba K, Su X, He L, Wondisford FE.
    J Biol Chem; 2022 Dec 24; 298(12):102708. PubMed ID: 36402444
    [Abstract] [Full Text] [Related]

  • 26. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA, Chan JL.
    Endocr Pract; 2010 Dec 24; 16(2):324-33. PubMed ID: 20061299
    [Abstract] [Full Text] [Related]

  • 27. Leptin replacement improves postprandial glycemia and insulin sensitivity in human immunodeficiency virus-infected lipoatrophic men treated with pioglitazone: a pilot study.
    Magkos F, Brennan A, Sweeney L, Kang ES, Doweiko J, Karchmer AW, Mantzoros CS.
    Metabolism; 2011 Jul 24; 60(7):1045-9. PubMed ID: 21081243
    [Abstract] [Full Text] [Related]

  • 28. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA, Cochran E, Kassai A, Brown RJ, Gorden P.
    Expert Rev Clin Pharmacol; 2016 Jul 24; 9(1):59-68. PubMed ID: 26465174
    [Abstract] [Full Text] [Related]

  • 29. Advanced Lipoprotein Analysis Shows Atherogenic Lipid Profile That Improves After Metreleptin in Patients with Lipodystrophy.
    Kinzer AB, Shamburek RD, Lightbourne M, Muniyappa R, Brown RJ.
    J Endocr Soc; 2019 Aug 01; 3(8):1503-1517. PubMed ID: 31620670
    [Abstract] [Full Text] [Related]

  • 30. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H, Vantyghem MC, Nobécourt E, Andreelli F, Archambeaud F, Bismuth E, Briet C, Cartigny M, Chevalier B, Donadille B, Daguenel A, Fichet M, Gautier JF, Janmaat S, Jéru I, Legagneur C, Leguier L, Maitre J, Mongeois E, Poitou C, Renard E, Reznik Y, Spiteri A, Travert F, Vergès B, Zammouri J, Vigouroux C, Vatier C.
    Diabetes Obes Metab; 2022 Aug 01; 24(8):1565-1577. PubMed ID: 35445532
    [Abstract] [Full Text] [Related]

  • 31. Failure of substrate-induced gluconeogenesis to increase overall glucose appearance in normal humans. Demonstration of hepatic autoregulation without a change in plasma glucose concentration.
    Jenssen T, Nurjhan N, Consoli A, Gerich JE.
    J Clin Invest; 1990 Aug 01; 86(2):489-97. PubMed ID: 2200805
    [Abstract] [Full Text] [Related]

  • 32. Treatment Options for Lipodystrophy in Children.
    Mainieri F, Tagi VM, Chiarelli F.
    Front Endocrinol (Lausanne); 2022 Aug 01; 13():879979. PubMed ID: 35600578
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program.
    Ajluni N, Dar M, Xu J, Neidert AH, Oral EA.
    J Diabetes Metab; 2016 Mar 01; 7(3):. PubMed ID: 27642538
    [Abstract] [Full Text] [Related]

  • 34. Effects of fasting and glucocorticoids on hepatic gluconeogenesis assessed using two independent methods in vivo.
    Goldstein RE, Rossetti L, Palmer BA, Liu R, Massillon D, Scott M, Neal D, Williams P, Peeler B, Cherrington AD.
    Am J Physiol Endocrinol Metab; 2002 Nov 01; 283(5):E946-57. PubMed ID: 12376321
    [Abstract] [Full Text] [Related]

  • 35. Long-Term Effects of Metreleptin in Rabson-Mendenhall Syndrome on Glycemia, Growth, and Kidney Function.
    Okawa MC, Cochran E, Lightbourne M, Brown RJ.
    J Clin Endocrinol Metab; 2022 Feb 17; 107(3):e1032-e1046. PubMed ID: 34718628
    [Abstract] [Full Text] [Related]

  • 36. Elevated gluconeogenesis and lack of suppression by insulin contribute to cystic fibrosis-related diabetes.
    Hardin DS, Ahn C, Rice J, Rice M, Rosenblatt R.
    J Investig Med; 2008 Mar 17; 56(3):567-73. PubMed ID: 18418124
    [Abstract] [Full Text] [Related]

  • 37. Thyroid Abnormalities in Patients With Extreme Insulin Resistance Syndromes.
    Kushchayeva YS, Kushchayev SV, Startzell M, Cochran E, Auh S, Dai Y, Lightbourne M, Skarulis M, Brown RJ.
    J Clin Endocrinol Metab; 2019 Jun 01; 104(6):2216-2228. PubMed ID: 30657911
    [Abstract] [Full Text] [Related]

  • 38. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K, Ali O, Akinci B, Foss de Freitas MC, Montenegro RM, Fernandes VO, Gupta D, Lou KJ, Tuttle E, Oral EA, Brown RJ.
    J Clin Endocrinol Metab; 2021 Jul 13; 106(8):e2953-e2967. PubMed ID: 33822100
    [Abstract] [Full Text] [Related]

  • 39. Glycerol induces G6pc in primary mouse hepatocytes and is the preferred substrate for gluconeogenesis both in vitro and in vivo.
    Kalemba KM, Wang Y, Xu H, Chiles E, McMillin SM, Kwon H, Su X, Wondisford FE.
    J Biol Chem; 2019 Nov 29; 294(48):18017-18028. PubMed ID: 31645433
    [Abstract] [Full Text] [Related]

  • 40. Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
    Muniyappa R, Abel BS, Asthana A, Walter MF, Cochran EK, Remaley AT, Skarulis MC, Gorden P, Brown RJ.
    J Clin Lipidol; 2017 Nov 29; 11(2):543-550. PubMed ID: 28502512
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.